Benefits
Reduced osteoarthritis pain (meta-analysis evidence)
A meta-analysis of 3 RCTs (n=287, median 3-month duration) found rosehip powder produced an effect size of 0.37 (95% CI 0.21-0.54) for pain reduction vs placebo. Number needed to treat = 6. Effect size is small-to-moderate but consistent across trials — comparable to other dietary supplements for OA pain (e.g., glucosamine).
Improved joint mobility
Rosehip powder significantly improved hip flexion vs placebo over 4 months. Patient-reported global assessment of disease severity, pain on movement, and pain at rest all improved significantly.
Reduced NSAID consumption
In OA patients, the rosehip group had reduced consumption of analgesics and NSAIDs vs placebo. Patients reported improved general wellbeing alongside pain reduction.
Anti-inflammatory CRP reduction
Rosehip powder supplementation has been associated with reduction in C-reactive protein after 4 weeks of supplementation in OA patients. Combined with the in vitro anti-chemotactic effect on neutrophils and monocytes, this supports an anti-inflammatory mechanism rather than simple analgesia.
Mechanism of action
GOPO galactolipid anti-inflammatory action
GOPO — (2S)-1,2-di-O-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]-3-O-β-D-galactopyranosyl glycerol — is the principal anti-inflammatory active. In vitro, GOPO inhibits chemotaxis of peripheral blood neutrophils and monocytes, reducing inflammatory cell infiltration into joint tissue. This is preserved only in cold-processed rosehip preparations; standard hot extraction destroys it.
Cytokine and matrix metalloproteinase suppression
GOPO reduces production of NO, PGE2, TNF-α, IL-1β, IL-6, and IL-12 by human blood cells. It also suppresses gene expression of matrix metalloproteinases, aggrecanases, TNF-α, and NF-κB — pathways central to cartilage degradation in osteoarthritis.
Antioxidant lipid composition
Rosehip provides ω-3 (α-linolenic acid) and ω-6 (linoleic acid) PUFAs, plus triterpenic acids (betulinic, oleanolic, ursolic acid), high vitamin C content (rosehip is a traditional vitamin C source), lycopene, and various polyphenols. Combined antioxidant capacity supports joint tissue against oxidative damage from inflammation.
Clinical trials
Random-effects pooled analysis using REML methods (Christensen, Bartels, Altman, Astrup, Osteoarthritis Cartilage 16(9):965-972).
3 clinical trials, total n=287 OA patients (145 rosehip, 142 placebo). Median trial duration 3 months. All 3 trials supported by manufacturer Hyben-Vital International.
Pooled effect size for pain reduction = 0.37 (95% CI 0.21-0.54). Number needed to treat = 6. Authors concluded rosehip powder produces a small-to-moderate but statistically significant pain reduction in OA patients vs placebo. Manufacturer-funding noted as a study limitation.
Randomized, double-blind, placebo-controlled crossover trial (Winther, Apel, Scand J Rheumatol 34(4):302-8).
94 patients with osteoarthritis of the hip or knee. Crossover design with rosehip powder 5 g/day vs placebo for 3 months each, with washout period.
Rosehip powder produced significant improvements vs placebo in WOMAC pain scores, joint stiffness, hip flexion, and patient-reported global assessment. 66% of patients reported reduction in pain on rosehip vs 35% on placebo. Established the foundational efficacy data and characteristic time-to-effect (~3 weeks).
Double-blind, placebo-controlled, randomized crossover trial (Rein, Kharazmi, Phytomedicine 11(5):383-91).
100 OA patients receiving 5 g/day rosehip powder (Hyben Vital, standardized Rosa canina subspecies) vs placebo for 4 months in crossover design.
Rosehip powder significantly reduced pain (p<0.0078) and improved general wellbeing vs placebo. Reduced consumption of rescue analgesics and NSAIDs. Established that the standardized cold-processed Rosa canina subspecies (preserving GOPO galactolipid) produces clinically meaningful OA symptom relief.